Dr. David Fajgenbaum, Perelman School of Medicine, University of Pennsylvania, says the pathology of this patient is consistent with iMCD. Importantly, other disorders such as lymphoma, autoimmune disorders, and EBV-related lymphoproliferation were excluded. This patient has the plasmacytic variant of iMCD, which is the most frequent pathologic variant of MCD. Other pathologies, such as hyaline vascular variety and mixed cellularity (which has features of both plasmacytic and hyaline vascular variant), can also occur in iMCD. Both the negative LANA-1 stain and the absence of detectable replicating HHV-8 virus in the peripheral blood point to the idiopathic form of MCD.
What is the most likely diagnosis for this patient?
Guess the Diagnosis: Case 1
Lisa B. is a 47-year-old female store owner from St. Louis, with a 10-month history of fatigue, night sweats, and weight loss.
Lisa’s pathology report shows the following findings:
In view of these findings, the hematologist orders further tests, which yield the following results:
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Superior Outcomes With Brentuximab Vedotin Triplet in Diffuse Large B-Cell Lymphoma
September 11th 2024The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.
Read More